In four healthy volunteers, we analyzed in detail the immediate in vivo effects on circulating neutrophils of subcutaneous administration of 300 pg of granulocyte colony-stimulating factor (G-CSF). Neutrophil activation was assessed by measurement of degranulation. Mobilization of secretory vesicles was shown by a decrease in leukocyte alkaline phosphatase content of the circulating neutrophils. Furthermore, shortly postinjection, FcyRlll was found to be upregulated from an intracellular pool that we identified by immunoelectron microscopy as secretory vesicles. Intravascular release of specific granules was shown by increased plasma levels of lactoferrin and by upregulation of the expression of CD= and CDllb on circulating neutrophils. Moreover, measurement of fourfold elevated plasma levels of elastase, URING RECENT YEARS granulocyte colony-stimulating factor (G-CSF)' has been used successfully in clinical studies to accelerate the recovery of neutrophil counts after cytostatic therapy and thus to reduce the occurrence of infections? In addition to its effect on the production of neutrophils, G-CSF also modulates several neutrophil functions. In an initial study in healthy volunteers, we focused on the characteristics of the neutrophils that were newly generated as a result of G-CSF on myeloid precursor cells.3 We found that G-CSF induces the production of phenotypically and functionally altered neutrophils with respect to Fcy receptor profile and antibody-dependent cellular cytotoxicity, respectively. As G-CSF acts also on mature neutrophils, we analyzed the immediate effects of G-CSF administration on the circulating neutrophils.
In four healthy volunteers, we analyzed in detail the immediate in vivo effects on circulating neutrophils of subcutaneous administration of 300 pg of granulocyte colony-stimulating factor (G-CSF). Neutrophil activation was assessed by measurement of degranulation. Mobilization of secretory vesicles was shown by a decrease in leukocyte alkaline phosphatase content of the circulating neutrophils. Furthermore, shortly postinjection, FcyRlll was found to be upregulated from an intracellular pool that we identified by immunoelectron microscopy as secretory vesicles. Intravascular release of specific granules was shown by increased plasma levels of lactoferrin and by upregulation of the expression of CD= and CDllb on circulating neutrophils. Moreover, measurement of fourfold elevated plasma levels of elastase, URING RECENT YEARS granulocyte colony-stimulating factor (G-CSF)' has been used successfully in clinical studies to accelerate the recovery of neutrophil counts after cytostatic therapy and thus to reduce the occurrence of infections? In addition to its effect on the production of neutrophils, G-CSF also modulates several neutrophil functions. In an initial study in healthy volunteers, we focused on the characteristics of the neutrophils that were newly generated as a result of G-CSF on myeloid precursor cells. 3 We found that G-CSF induces the production of phenotypically and functionally altered neutrophils with respect to Fcy receptor profile and antibody-dependent cellular cytotoxicity, respectively. As G-CSF acts also on mature neutrophils, we analyzed the immediate effects of G-CSF administration on the circulating neutrophils.
It is known that G-CSF primes neutrophils for superoxide production stimulated by FMLP when used in in vitro experim e n t~~.~ and when applied in Furthermore, in vitro exposure of neutrophils to G-CSF increases the affinity of the adhesion protein L-selectin for its carbohydrate ligand.' This is followed by a decrease in surface expression of Lselectin, due to shedding.* Finally, in vitro G-CSF induces an increased expression of the P2-integrin CD1 lb?IO which is also found shortly after G-CSF administration in Apparently, G-CSF induces the mobilization of the intracellular pool of CD1 lb.'"13
After administration of G-CSF an immediate drop in neutrophil counts has been rep~rted,'~." which is most likely the result of neutrophil activation. In vitro activation of neutrophils is reflected by mobilization of the different intracellular neutrophil compartments. Of these, the secretory vesicles form the fastest mobilizable compartment.'6"8 The exocytosis of specific granules can be triggered in primed neutrophils by several neutrophil agonists, whereas degranulation of azurophil granules is only achieved in the presence of cytochalasin B, which interferes with the function of the cytoskeleton." There are no reports on degranulation of neutrophils after G-CSF exposure. Therefore, we analyzed in healthy volunteers the degranulation of circulating neutrophils upon in vivo application of G-CSF. We studied the release of the content of secretory vesicles, specific granules, and azurophil granules by determination of alkaline phosphatase,I6 lactoferrin," and elastase-a1 AT complexes,'' respectively. Furthermore, the expression of CDllb (C3bi receptor), localized in secretory vesicles and the specific granules,".'2.20 of CD66b (NCA95;'.** formerly named CD67), mainly localized in the specific granules;' and of CD63 (azurophil granule markerI7), was studied by flow cytometric analysis of the circulating neutrophils. We found that all three intracellular compartments of neutrophils are mobilized after G-CSF administration in vivo. These results were compared with the effect of G-CSF on neutrophils in whole blood cultures in vitro.
cal examination, and routine laboratory investigation were normal in all subjects. They did not use any medication, did not smoke, and had no febrile disease in the month before the study. The volunteers were under medical observation during the first day of the trial.
Venous blood samples (EDTA anticoagulated) were obtained immediately before the administration of G-CSF and 5, 15, and 30  minutes and 1, 2, 4, 8, 12, 24, 48, 72, 96 , and 144 hours thereafter. Additional plasma samples were obtained 7, 8, 10, 12, and 20 days postinjection. Total leukocyte counts and differential counts were determined with the H1 system (Technicon Instruments, Tarrytown, NY). Leukocyte differential counts (morphologic characterization of Jenner-Giemsa-stained slides) and determination of leukocyte alkaline phosphatase (LAP) scores were performed manually on smears of non-anticoagulated blood. For measurement of released proteins, EDTA plasma was immediately stored at -20°C for subsequent determination.
Measurement of G-CSFplasma levels. G-CSF levels were measured with a commercial enzyme-linked immunosorbent assay (ELSA) test kit (Quantikine Human G-CSF Immunoassay, R&D Systems, Minneapolis, m), according to the manufacturer's instructions. Briefly, 100 pL of plasma or dilutions of plasma were incubated for 2 hours in a microtiter plate precoated with an anti-G-CSF monoclonal antibody (MoAb). After washing, bound G-CSF was detected by horseradish peroxidase-labeled polyclonal rabbit anti-G-CSF Ig. The concentration of G-CSF in a plasma sample was determined by comparison with a provided standard of dilutions of recombinant human (rh) G-CSF. The lower detection level of the assay was 10 pg/mL.
Immunophenotypic analysis. Blood samples were used immediately for flow cytometric analysis. Erythrocytes were lysed by diluting (15, vol/vol) peripheral blood with ice-cold isotonic NI-L, CI solution (155 mmoVL NHCI, 10 mmoVL KHCO,, 0.1 mmoVL EDTA, pH 7.4) for 10 minutes. The cells were centrifuged in the cold, and the residual erythrocytes were lysed for 3 more minutes. The remaining white blood cells were washed twice and resuspended at 15 X 106/mL in cold phosphate-buffered saline (PBS)lbovine serum albumin (BSA), 0.2% wt/vol. Indirect immunofluorescence was performed according to standard techniques, with a panel of murine MoAbs against myeloid antigens. The cells were incubated with appropriate dilutions of MoAb in PBS supplemented with 0.2% BSA (wtlvol) and 0.1% wtlvol NaN,. Binding of the MoAb was visualized with fluorescein isothiocyanate (FITC)-labeled F(ab')2 fragments of polyclonal goat IgG against mouse Ig. Flow cytometric analysis was performed with a FACScan (Becton Dickinson, San Jose, CA). Neutrophils were easily discriminated from lymphocytes and monocytes by their characteristic forwardhideward scatter. Measurement was made after live gating on neutrophils. In this way, phenotypic changes due to isolation procedures were circumvented." The following antibodies were used: CLB irrelevant murine control MoAb of the IgGl and IgG2a subclass, CLB-B2.12 (CDllb), CLBFcRgranl', and 3G8% (CD16), IV.3 (CD32):
CLB-435 (CD63):6 B 13.9 (CD66b, formerly named CD67):' and FITCconjugated goat-antimouse-Ig [CLB G26M17F; F(ab')2 FITC]. The 3G8 and IV.3 MoAbs were from Medarex (West Lebanon, NH); all other MoAbs were produced in our own laboratory, and their reactivity was established during the Fourth International Workshop on Human Leukocyte Differentiation Antigens (Vienna, Austria, 1989) .
Determination of LAP activity in neutrophils after G-CSF administration in vivo. Non-anticoagulated blood smears were dried in air, fixed with ice-cold 10% formalin methanol (vol/vol) for 1 minute, and then incubated with a solution containing Fast-Blue for 15 minutes. After this incubation, the blood smears were stained according to Jenner-Giemsa. Neutrophils showed alkaline phosphatase as blue deposit. The degree of activity in each cell was rated according to the number of precipitated blue granules in the cytoplasm. The normal range of score in our laboratory is 0.2 to 0.5 as determined in 100 neutrophils.
Whole blood incubations. Freshly drawn sodium-heparin anticoagulated blood was incubated with either titrated concentrations of G-CSF, FMLP (1 pmoVL), or PBS in 24-well plates at 37°C. The incubation was ended by dilution of the blood with ice-cold isotonic NH,Cl solution. Subsequently, the leukocytes were isolated and stained as described in "Immunophenotypic Analysis" and studied by flow cytometry. Plasma was isolated from simultaneously activated whole blood samples. Whole blood incubations with FMLP (1 pmoVL) and cytochalasin B (5 pg/mL) for 30 minutes at 37°C were performed to induce maximal release of lactofemn and elastase.
Activation of neutrophils. The purification and subsequent activation of neutrophils with FMLP (1 pmoVL) or titrated G-CSF concentrations was performed as described p r e v i o~s l y .~~ After activation of the cells, the supernatant was harvested, and released FcyRIII was measured in the sFcyRUI radioimmunoassay (see below). The amount of released FcyRIII was expressed relatively to the total FcyRIII content in a lysate of resting neutrophils.
sFcyRIII radioimmunoassay. Soluble FcyRIII levels were determined by a radioimmunoassay (RIA) essentially as described before." In short, CLBFcRgranl coupled to CNBr-activated Sepharose 4B was incubated with plasma for 16 hours at room temperature by head-over-head rotation in 2-mL polystyrene tubes. Bound sFcyRIII was detected by a subsequent incubation (5 hours at room temperature) with '251-labeled FcyRIII MoAb BW209/2 (Dr R. Kurrle, Behringwerke AG, Marburg, Germany). Samples were tested in triplicate. Results were expressed as percentages of sFcyRIII in a pool of 80 plasma samples from normal donors. Dilutions of this pool were tested in each assay as a standard.
Determination of elastase and lactoferrin release. Elastase-a 1 -antitrypsin (elastase-a1 AT) complexes and lactofemn were measured using a RIA as described previously?8 All polyclonal antisera and MoAbs used in these assays were produced in our own laboratory. Briefly, immunoglobulin enriched fractions of a rabbit antiserum against human-neutrophil elastase or MoAb 13.17 (anti-lactoferrin) were coupled to CNBr-activate Sepharose beads and incubated with plasma samples (4 hours). The beads were washed and incubated (16 hours) with '*%labeled MoAb AT15 directed against a l A T or polyclonal '251-labeled anti-lactofemn. Levels of elastasea1AT complexes and lactofemn were expressed as nanograms per milliliter with preformed complexes and lactofemn as standards, respectively.
Immuno-electron microscopy. Leukocytes were isolated as described under immunophenotypic analysis, fixed for 2 hours at room temperature in a graded (2% to 8%) paraformaldehyde (PFA) series in PBS to preserve the antigenicity of FcyRIII: ' and pelleted in 10% gelatin. Subsequently, the samples were prepared for cryosectioning and immunolabeling as described previously.'2 Double-labeling experiments were performed with mouse MoAb CLBFcRgranl (anti-FcyRJII) followed by incubation with rabbit-antimouse Ig and goat-antirabbit Ig conjugated to 5 nm gold (all anti-rabbit gold conjugates were from Amersham Nederland, 's-Hertogenbosch, The Netherlands). Albumin was detected by rabbit-antihuman albumin (CLB, Amsterdam, The Netherlands), and lactoferrin was detected with rabbit-antihuman lactofemn (Cappel Laboratories, Cochranville, PA). Both sera were visualized with goat-antirabbit Ig conjugated to 15 nm gold. For the controls, the primary antibody was replaced by a nonrelevant murine or rabbit Ig. After immunolabeling, the cryosections were embedded in a mixture of methylcellulose and uranyl acetate. All sections were examined with a Philips CM10 electron microscope (Eindhoven, The Netherlands).
To study the mobilization of secretory vesicles, whole blood was incubated as described above and after 30 minutes of incubation For personal use only. on October 23, 2017. by guest www.bloodjournal.org From fixed with 1% PFA. Subsequently, the erythrocytes were lysed as described in "Immunophenotypic Analysis." The remaining leukocytes were treated with a mixture of 0.5% glutaraldehyde and 4% PFA for 2 hours and further processed as described above. Cryosections were incubated with anti-albumin antiserum and 10 nm goldconjugated goat-anti-rabbit Ig.
For quantitative analysis, micrographs of 20 randomly selected cell profiles containing two or three lobes of the nucleus were taken for each experiment at a primary magnification of 9.8 X lo3. The cells were further enlarged 2. 5 times, and the number of positive secretory vesicles, large vesicles, and gold particles on the cell membrane were scored.
Statistical analysis. Student's t-tests were performed for paired differences. A two-sided P value < .05 was considered to indicate a significant difference.
RESULTS

Peripheral blood G-CSF levels and neutrophil counts.
Preinjection endogenous levels of G-CSF measured in plasma of two volunteers were 53 pg/mL and 44 pg/mL (Fig  l) , which is within the normal range (< 78 pg/mL, n = 48). At 5 minutes postinjection, 30-fold elevated levels of G-CSF were measured in the plasma sample. Peak levels of G-CSF were measured at 4 hours postinjection (25,000 pg/mL and 44,000 pg/mL), and at 24 hours, G-CSF levels were approximately 300 p g / d for both donors. (marker of specific granules) on the remaining neutrophils in the circulation (Fig 2A and 2B , respectively). At this time, peak levels of CD66b were measured, and the expression of CD66b remained elevated until 4 hours postinjection. CD 1 1 b was maximally expressed at 2 hours postinjection and returned to baseline levels at 4 hours postinjection. As shown in Fig 2C, the expression of FcyRIII was increased shortly after G-CSF administration, followed by a strong decrease in expression. However, the response proved to be heterogeneous: a significant elevation of FcyRIII expression was found in two donors, whereas the two other donors showed a constant level of expression of FcyRIII until 1 hour postinjection, followed by a decreased FcyRIII expression. Because activation of neutrophils results in shedding of FcyRIII," we determined whether FcyRIII was released in response to G-CSF by measuring the plasma levels of sFcyRIII. Indeed, sFcyRIII levels were increasing during the first hours postinjection in all donors (Fig 2C) . Finally, no significant change in expression of CD63 (marker of azurophil granules), FcyRII, or L-selectin was found (data not shown).
Degranulation of neutrophils after G-CSF administration in vivo. The intracellular LAP content (marker of secretory vesicles) of the neutrophils circulating during the neutropenic phase was found to be significantly decreased. Moreover, during the first 4 hours postinjection LAP values remained at this low level (Fig 2D) . Thereafter, a sharp increase in LAP content was observed, probably as a result of increased LAP production, as was discussed in our previous report.3 With respect to degranulation of the two other intracellular neutrophil compartments, G-CSF administration induced within 1 hour a significant rise in plasma levels of both lactoferrin (specific granules) and elastase-a 1 AT complexes (azurophil granules; Fig 3A and 3B, Compared with lactofenin levels, which had returned to preinjection values at 24 to 48 hours postinjection, the levels of elastase-a1AT returned more gradually to baseline levels. Furthermore, a second transient elevation in the plasma levels of lactofenin, peaking at 7 days postinjection, was found. Expression of activation markers on neutrophils after in vitro exposure to G-CSF. The stimulatory effect of G-CSF was studied in vitro by incubation of freshly drawn whole blood with various concentrations of G-CSF (1 to 100 ng/ mL). Concomitantly, samples were also incubated with 1 pmoVL FMLP, a concentration known to induce fusion of both secretory vesicles and specific granules with the cell membrane.''." A time-and G-CSF concentration-dependent upregulation of the expression of CD1 Ib and CD66b was observed (Fig 4A and 4B) . Based on these results and on G-CSF plasma levels measured shortly postinjection in vivo (Fig l) , we performed additional whole blood incubations using a G-CSF concentration of 10 ng/mL. As shown in Fig 4C, trast to the expression of all other antigens studied, nonstimuthe level of sFcyRII1 in the plasma that was harvested at lated neutrophils exhibited a temporarily decreased the end of the incubation, which argues against shedding of expression of FcyRIII during the incubation period. The FcyRIII. G-CSF also did not induce shedding of FcyRIII, decrease in expression was not reflected by an increase in neither in whole blood cultures nor by incubation of isolated neutrophils (13% ? 2% of total neutrophil FcyRIII was released without stimulus, 10% 2 3% by G-CSF (10 ng/ mL), and 40% t 4% by Fh4LP; n = 4). Expression of CD63 and FcyRIII were not changed significantly by G-CSF (10 ng/mL), whereas the expression of L-selectin decreased significantly by G-CSF to 79% L 2% of the baseline level (n = 3, data not shown).
Degranulation after in vitro activation of neutrophils by G-CSF. In vitro incubation of whole blood with G-CSF (10 ng/mL) resulted in the release of lactoferrin but not in the release of elastase. After G-CSF activation, lactoferrin levels increased from 83 +-28 ng/mL to 191 2 2 ng/mL (1.9 5 0.01-fold increase, n = 3; Fig 5) . FMLP stimulation induced a 14.7 2 2-fold increase of lactoferrin levels (Fig  5, n = 3) . G-CSF did not induce release of elastase, not even when the incubation period was extended to 4 hours and G-CSF concentrations of 100 ng/mL were tested (n = 3, data not shown). In contrast, elastase release was observed in blood samples incubated with either 1 pmoVL FMLP alone or with 1 pmol/L FMLP in combination with 5 pg/mL cytochalasin B (465 5 42 ng/mL elastase-a1AT per milliliter and 1,340 +-235 ng/mL, respectively).
Immuno EM studies on the intracellular localization of FcyRIII and the activation of neutrophils upon addition of G-CSF. Albumin is a marker of secretory vesicles detectable by immuno (Fig 6a) . We found co-localization of FcyRIII and albumin (Fig 6b) but not of FcyRIII and lactoferrin, a marker of specific granules (Fig 6c) . Thus, the intracellular pool of FcyRIII is formed by secretory vesicles. For personal use only. on October 23, 2017 . by guest www.bloodjournal.org From Leukocytes that were isolated after whole blood incubations (30 minutes at 37°C) were fixed and measured by immunogold staining for albumin in frozen thin sections. Micrographs of 20 cell profiles were examined for each incubation.
*Whole blood was fixed immediately after venapunction. t PBS was added instead of an activator.
* Number of positive vesicles. § Gold particles on the cell surface membrane.
Furthermore, by semiquantitative EM we analyzed the effect of G-CSF on the mobilization of secretory vesicles. Table 1 shows that after G-CSF incubation a decrease in the number of secretory vesicles was found. The effect of FMLP on secretory vesicle mobilization was more pronounced (Table l), similar to the results obtained in the experiments on G-CSF-and FMLP-induced upregulation of CDllb and FcyRIII (Fig 4A and 4C) . Like FMLP, G-CSF induced the formation of large vesicles (Fig 7) and fusion of some of these vesicles with the surface membrane was observed (Fig   7a) . Moreover, labeling of albumin localized on the plasma membrane (Fig 7, a and b) was significantly higher in incubations with G-CSF and FMLP than in the controls.
DISCUSSION
We examined the immediate effects of in vivo administration of G-CSF on circulating neutrophils. We found that G-CSF induces in vivo activation of neutrophils, as shown by the mobilization of secretory vesicles (LAP, CD1 lb) as well as specific granules (lactoferrin, CDllb, and CD66b) and azurophil granules (elastase alAT).
Mobilization of secretory vesicles. Fusion of secretory vesicles with the plasma membrane was already observed at 30 minutes postinjection, as reflected by a decrease in intracellular alkaline phosphatase content of the neutrophils and by an increase in membrane-bound CD1 lb. We confirmed by immuno EM that secretory vesicles mobilize after G-CSF treatment in vitro (Table 1) . Using alkaline phosphatase as a marker in immuno EM studies, Kobayashi and Robinson3' described in thick sections an intracellular neutrophil compartment that, after activation with FMLP, fused to form a few elongated tubular structures that associated with the cell membrane, resulting in cell surface reaction for alkaline phosphatase. Similarly, using ultrathin cryosections and albumin as a marker, we observed by immuno EM the formation of so-called large vesicles after both G-CSF and FMLP incubation. Some of these vesicles were in close association with the plasma membrane. We suppose that the compartment marked by is the same as the compartment described by Kobayashi and R~binson.~' Thus, these large vesicles probably reflect the activation-dependent fusion of secretory vesicles, induced by G-CSF and FMLP.
Furthermore, we found elevated staining of albumin along the plasma membrane after G-CSF and FMLP incubation. Whether this reflects the exocytosis or an increased endocytosis of albumin, as has been described for has to be evaluated.
FcyRIII is present in secretory vesicles. FcyRIII, one of the Fc receptors for complexed IgG, was found to be upregulated by G-CSF. FcyRIII has been found in multiple vesicles in ne~trophils?~ and subcellular fractionation studies have suggested the presence of FcyRIII both in the specific granules and in the alkaline phosphatase-containing cell fract i~n .~~
In this study, we demonstrated by immuno EM that the intracellular pool of FcyRIII is formed by secretory vesicles. The presence of FcyRIII in these easily mobilizable vesicles assures the quick replenishment of this IgG receptor in case it has been occupied or lostz7 during phagocytosis. FcyRIII and CD1 l b are found in close proximity on the cell membrane,35 and cooperation of both molecules in signal transduction has been ~o s t u l a t e d .~~
The presence of FcyRIII and CD1 l b in the same highly mobilizable intracellular compartment might facilitate an associated expression after cell activation.
Although FcyRIII, alkaline phosphatase; and CD1 l b are present in the same intracellular compartment, these antigens showed different kinetics after in vivo G-CSF administration. We observed in all donors secretory vesicle mobilization until 4 hours after G-CSF administration, as judged by the decrease in alkaline phosphatase content and increased CD1 l b expression, whereas upregulation of FcyRIII membrane-expression was found in only two out of four donors and no longer than 30 minutes postinjection (Fig 2C and 2D) . However, in vitro G-CSF incubation induced upregulation of the expression of both CDllb and FcyRIII in all tested donors, also in the two in vivo "non-responders". A similar discrepancy between upregulation of FcyRIII in vivo and in vitro has been described by Werfel et al.37 These investigators showed a significant upregulation of FcyRIII after C5a incubation of whole blood in vitro, whereas during hemodialysis, which leads to C5a generation, elevated FcyRIII expression on the neutrophils was found in only two out of six patients. We wondered whether this discrepancy was caused by activation-induced release of FcyRIII from the cell membrane." Indeed, in all donors we measured increasing plasma levels of sFcyRIII, accounting for the decreased membrane expression in the first hours postinjection. The level of sFcyRIII, which has a half time of 1.5 days,38 remained relatively constant after 4 hours postinjection. Because FcyRIII expression increases with the maturation of neutrop h i l~,~~ the ongoing decrease in FcyRIII expression after 4 hours postinjection might be explained by the influx of storage-pool granulocytes with lower FcyRIII expression. In vitro, after exposure to G-CSF, we only observed upregulation of FcyRIII expression and no shedding of FcyRIII, neither in whole blood cultures nor by incubation of purified neutrophils. Apparently, G-CSF is a more potent activator of neutrophils in vivo than in vitro.
Degranulation. As to specific granule degranulation, G-CSF induced upregulation of CD1 l b and CD66b and rapid release of lactofenin both in vivo and in vitro. With respect For personal use only. on October 23, 2017. by guest www.bloodjournal.org From to the number of circulating neutrophils, in vivo release of lactofemn was most prominent during the first 2 hours after G-CSF administration. Rising levels of lactofemn were measured simultaneously with increased expression of CDllb and CD66b on the circulating neutrophils, reflecting the release of lactofemn by circulating neutrophils. Lactofemn levels peaked at 4 hours postinjection, at which time point peak levels of G-CSF also were measured. As late as 3 days postinjection a second transient increase in lactoferrin plasma levels was noticed, peaking at 7 days postinjection. In close analogy with previous observations on levels of s F c~R I I I ,~*~* this second peak most likely reflects the turnover of the abundantly produced neutrophils in the tissues, ultimately resulting in elevated plasma levels of sFcyRIII and lactoferrin.
In vivo, we detected the release of azurophil granules, in sharp contrast to our in vitro observations. Expression of CD63, a specific marker for fusion of azurophil granules with the cell membrane," was not detected on neutrophils in response to G-CSF in vivo nor in vitro. In vivo, strongly activated neutrophils may have left the circulation and therefore be underrepresented in the blood samples used for flow cytometric analysis. Several observations are in concordance with this hypothesis: (1) After G-CSF administration, the circulating neutrophils did not exhibit decreased expression of L-selectin, in contrast to in vitro observations (this report, Spertini et a1,8 and Yong and Linch"). ( 2) The G-CSFinduced upregulation of CD1 1 b expression on neutrophils in vitro was twice as high than in vivo. (3) Increased levels of CD1 l b on the circulating neutrophils were observed only up to 2 hours postinjection, whereas neutrophil activation in terms of granule content release was observed as late as 4 to 8 hours after administration. We propose that in vivo elastase release by G-CSF-activated neutrophils is induced by additional stimulation, which could be caused by interactions in the endothelial microenvironment. This might explain the pattern of elastase release, which is delayed and prolonged when compared with lactofemn. The relatively prolonged elevation of elastase-a1AT levels cannot be explained by a difference in half times between elastase-alAT and lactoferrin (both 45 to 60 minute^^'.^'). Migration of neutrophils over monolayers of endothelial cells in vitro induced release of specific granules and not azurophil granu l e~,~* therefore, neutrophil migration to the tissues alone might not account for the observed release of elastase. However, whether exposure to G-CSF influences the mobilization of these granules during migration has to be evaluated.
Functional G-CSF receptors have been detected on monoc y t e~. ' ,~~
In accordance with Lindemann et al,I4 we observed a decrease in the number of circulating monocytes at 30 minutes postinjection (base line values, 0.34 t 0.03 X lo9/ L; 30 minutes postinjection, 0.15 ? 0.03 X 109/L; P < .05), whereas the numbers of circulating lymphocytes and platelets were not influenced significantly by G-CSF administration. Because we did not detect elevated plasma levels of interleukin (IL)6, IL8, or tumor necrosis factor a (TNFa) after G-CSF administration (data not shown), we have no indications that a possible concomittant activation of monocytes contributes to a more potent neutrophil activation in vivo. Furthermore, in vitro, simultaneous incubations of whole blood with different concentrations of G-CSF and IL8 did not result in a synergistic activating effect or release of elastase (data not shown). Nevertheless, subsequent activation of the neutrophils might occur after the margination of the neutrophils.
We have shown that G-CSF administration to healthy volunteers results in immediate and significant neutrophil degranulation. According to the literature and to our own observations, the G-CSF-induced neutrophil activation apparently does not result in obvious clinical symptoms in healthy volunteers.
